Auxilium Pharmaceuticals — Investor Presentation (May 2010)
44 slides from Auxilium Pharmaceuticals's investor presentation, May 4, 2010
Slide 1: May 2010
May 2010 (NASDAQ: AUXL) Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value ® Note: Seeking partners for Transmucosal film product candidates
Slide 4: XIAFLEX: Transforming Treatment
g A’ PT collagenase clostridium histolyticum TRANSFORMING TREATMENT oc esasr-an5-01 Rconly collagenase clostridium histolyticut (0.9 mg per vial for injection for intralesional use ‘Attention: Dispense the e- Medication Guide to each: sp de
Slide 5: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity Potential to be the only effective non-surgical treatment for two high unmet needs: Approved on February 2, 2010 for Dupuytren’s Contracture in U.S. Promising phase IIb results in Peyronie’s disease Well-characterized mode of action Worldwide rig
Slide 6: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients Excessive collagen deposition in fascia of hand Nodules represent early, active form Cords develop over time, are palpable, and result in contractures Quality of life and daily activities can be significantly affected Surgery has been the current
Slide 7: Treatment Options Historically Limited to Invasive Surgery
Treatment Options Historically Limited to Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective Surgery Needle fasciotomy/ aponeurotomy Amputation Non-surgical options > Splinting > Physical therapy > Corticosteroids
Slide 8: XIAFLEX Offers an Improved Mechanism of Action
XIAFLEX Offers an Improved Mechanism of Action Clostridial collagenase is faster and more efficient than human collagenase – Activity of XIAFLEX further enhanced by optimizing the ratio of collagenases in the product End products Fast cleavage Human collagenase Human collagenase (MMP) (MMP) Slow cle
Slide 9: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture
XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture
Slide 10: A Significant Number of Dupuytren's Patients Benefited from XIAFLEX
A Significant Number of Dupuytren’s Contracture Patients Benefited from Treatment with XIAFLEX
Slide 11: Early Intervention with XIAFLEX May Be the Most Effective Approach
Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach Hurst et al. NEJM 2009 N=248 N=125 Keith Denkler, M.D. Plast. Reconstr. Surg., 115802, 2005 Dupuytren’s Fasciectomies in 60 Consecutive Digits using lidocaine with epinepherine and no tournequet
Slide 12: XIAFLEX Was Well-Tolerated in Phase III Studies
XIAFLEX Was Well-Tolerated in Phase III Studies Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days across studies Serious Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of >260
Slide 13: XIAFLEX is a First-line Nonsurgical Option for Dupuytren's Contracture
XIAFLEX is a First-line Nonsurgical Option for Patients with Dupuytren’s Contracture Efficacy should compare favorably to surgery Primary endpoint of 5° for both MP and PIP joints reached with statistical significance in multiple studies Secondary endpoints support commercial uptake Early interventi
Slide 14: Targeting the Eligible Patient Population Should Drive U.S. Market Development
Targeting the Eligible Patient Population Should Drive Development of the U.S. Market to Its Full Potential 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data Based Projections (BESS database used, Medicare 5% database also use
Slide 15: XIAFLEX Commercial Strategy is Tailored to Customer Needs
XIAFLEX Commercial Strategy is Tailored to Customer Needs 1. ~ 7,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists Over 1100 physicians have attested to training and eligible to receive XIAFLEX as of April 30 2. ~ 100 field based personne
Slide 16: XIAFLEX Price of $3,250 Determined Following Stakeholder Assessment
XIAFLEX Price of $3,250 Determined Following Detailed Assessment Of Key Stakeholder Drivers DRIVERS: Financial risk vs. return Could provide reimbursement on par with surgery Shorter procedure to allow larger volumes to be treated and free up time for other procedures DRIVERS: Surgery cost vs. value
Slide 17: Reimbursement Process and Procedures May Provide Headwinds
Reimbursement Process and Procedures May Provide Headwinds Accounts naive to the reimbursement process will need customized support Miscellaneous J and CPT codes will be used Establishment of new product specific J code expected for 2011 and procedure codes (CPT) expected in 2012 Claims processing a
Slide 18: Key Objectives for U.S. XIAFLEX Launch in 2010
Key Objectives for U.S. XIAFLEX Launch in 2010 Position XIAFLEX as the non-surgical treatment alternative for physicians, payers and patients Achieve high awareness among targeted physicians and diagnosed patients Get targeted physicians through training and into distribution database Assist physici
Slide 19: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated High disease prevalence Based on literature, ~ 6M to 11M patients in U.S. have a Dupuytren’s pit, nodule or cord, but only ~ 300,000 new patients annually diagnosed in U.S. Sustainable patient pool New patients within an ageing p
Slide 20: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture U.S. Orphan Drug designation granted on May 23, 1996 provides exclusivity for 7 years post-approval in February 2010 Market Exclusivity expected in U.S. for 12 years post-approval, per 2010 Patient Protection and Affordable Care Act Market Exclusivit
Slide 21: XIAFLEX Supply Chain
XIAFLEX Supply Chain API produced in Horsham, PA 2 ° - 8 ° C storage expected at launch Annual capacity at current yield should be sufficient for several years of global launch expectations 1 manufacturing train in use and validated; capacity to expand for future demand Fill and Lyophilization: Holl
Slide 22: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Scarring phenomenon affecting the tunica albuginea Plaques show excessive collagen deposition Potential Symptoms > Pain with erection, penile curvature/ devia
Slide 23: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: - 2353;Rhoden et al: Int J. Impot Res :13 : - 293; La Pera et al : EUR Urology 2001: :525 - 530. Smith BH. Am J Clin Pat
Slide 24: Current Surgical Options Are the Treatment of Last Resort
Current Surgical Options Are theTreatment of Last Resort The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side Post-surgically, graft or prosthetic may be required Cost of surgery in U.S. is ~$10-12K Patients are highly motivated to attem
Slide 25: Unapproved Treatments for Peyronie's Disease Have Had Little Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success Verapamil Vitamin E Colchicine Potassium aminobenzoate (Potaba) Tamoxifen Interferon alpha-2a Corticosteroids Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser and ultrasound th
Slide 26: Promising Phase IIb Data in Peyronie's Disease
Promising Phase IIb Data in Peyronie’s Disease Overall – Significant XIAFLEX effect – Reduction of penile curvature – Improvement in Peyronie’s Disease Bother (PRO Domain) XIAFLEX With Modeling – Significant effect in both penile curvature and Peyronie’s disease bother endpoints XIAFLEX Without Mode
Slide 27: Overall Change in Penile Curvature Improved from Baseline – Week 36
Overall Change in Penile Curvature Improved from Baseline – Week 36
Slide 28: Overall Mean Score Change Peyronie's Disease Bother Domain
Overall Mean Score Change Peyronie’s Disease Bother Domain of the Patient Reported Outcome (PRO) Improved from Baseline – Week 36
Slide 29: Next Steps for Peyronie's Disease
Next Steps for Peyronie’s disease Anticipate end of phase II meeting with FDA in 2Q10 to discuss: – Validation of PRO – phase III trial design Anticipate commencing U.S. phase III study in 2H10
Slide 30: Extensive Market Research Performed with Peyronie's Surgeons
Extensive Market Research Performed with Peyronie’s Surgeons Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and 383 have given feedba
Slide 31: Annually, >210,000 Peyronie's Candidates Could Exist between U.S. and Europe
Annually , > 210,000 Peyronie ’ s Candidates Could Exist between U.S. and Europe
Slide 32: XIAFLEX I.P. Position for Peyronie's Disease
XIAFLEX I.P. Position for Peyronie’s Disease U.S. Orphan Drug designation granted on January 18, 1996 provides exclusivity for 7 years post-approval Market Exclusivity expected in U.S. for 12 years post-approval from first indication, per 2010 Patient Protection and Affordable Care Act Market Exclus
Slide 33: Strategic Partnership with Pfizer for XIAFLEX in EU
Strategic Partnership with Pfizer for XIAFLEX in EU Strong working relationship with goal to obtain EMA approval Auxilium is primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. Pfizer is primarily responsible for: European territ
Slide 34: Testim 1% Testosterone Gel: Near-Term Growth Driver
Testim ® 1% Testosterone Gel: Near-Term Growth Driver
Slide 35: Testim Maintains Double-Digit Growth in TRT Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile Recent study indicates 39% of U.S. males over 45 yrs are hypogonadal*
Slide 36: Patient Results Were Proven in Clinical Studies
Patient Results Were Proven in Clinical Studies 16 clinical studies involving approx. 1,800 patients > largest placebo-controlled study ever conducted Clinical trial of Testim ® vs. AndroGel ® > Testim provides 30% higher testosterone absorption (p<0.001)
Slide 37: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data Gel Segment Growth ($) February 2010 L12M: 29.9%
Slide 38: Continuing Track Record of Consistent Revenue Growth
Continuing Track Record of Consistent Revenue Growth $44.2M
Slide 39: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use claims for Test
Slide 40: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part
FDA Has Granted Our Citizen's Petition In Part And Denied It In Part Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic versions
Slide 41: 1Q 2010 Financial Results and 2010 Guidance
Testim Revenues $44.2 $34.7 $185-195 R&D Expense* $8.5 $13.5 $50-60 SG&A Expense* $36.1 $26.4 $160-170 Net Loss ($8.6) ($13.2) N/A Stock – Based Comp Expense (* included) $3.8 $4.5 $22-25 Cash & Cash Equivalents $175.8 1Q 2010 Financial Results and 2010 Guidance ($ Millions) Q1 ’10 Q1 ’09 Guidance C
Slide 42: Strategic Priorities in 2010
Strategic Priorities in 2010 Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; Support Pfizer in the ongoing regulatory review of the EMA Dupuytren’s submission and prepare for their potential EU approval; Commence phase III for XIAFLEX in Peyronie’s disease, assuming a successf
Slide 43: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value ® Note: Seeking partners for Transmucosal film product candidates
Slide 44: Auxilium Management Contact
Auxilium Management Contact James E. Fickenscher/CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 jfickenscher@auxilium.com William Q. Sargent Jr./ VP IR Auxilium Pharmaceuticals, Inc. (484) 321-5900 wsargent@auxilium.com (NASDAQ: AUXL)
Auxilium Pharmaceuticals — Investor Presentation (May 2010) on 6ix